{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:50:29Z","timestamp":1790059829957,"version":"4.0.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI137814"],"award-info":[{"award-number":["R21AI137814"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>\n            Tigecycline is used in multidrug regimens for salvage therapy of\n            <jats:named-content content-type=\"genus-species\">Mycobacterium abscessus<\/jats:named-content>\n            infections but is often poorly tolerated and has no oral formulation. Here, we report similar\n            <jats:italic>in vitro<\/jats:italic>\n            activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of\n            <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n            complex.\n          <\/jats:p>","DOI":"10.1128\/aac.00470-19","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T11:51:02Z","timestamp":1554378662000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":108,"title":["<i>In Vitro<\/i>\n            Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of\n            <i>Mycobacterium abscessus<\/i>"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1721","authenticated-orcid":false,"given":"Amit","family":"Kaushik","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumide","family":"Martins","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Parrish","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz071"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/2109.141634"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0310OC"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-231"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1610.091201"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2303.161827"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207983"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0234"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02623-18"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01275-08"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijs.0.63969-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-015OI"},{"key":"e_1_3_2_19_2","volume-title":"CLSI document M24-A2;","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2; vol 31, no 5. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-18"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2006.apm_390.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3164-3167.2002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1684-1182(10)60063-1"},{"key":"e_1_3_2_24_2","first-page":"73","article-title":"Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by SensiTitre RAPMYCO panel","volume":"35","author":"Cavusoglu C","year":"2012","unstructured":"Cavusoglu C, Gurpinar T, Ecemis T. 2012. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by SensiTitre RAPMYCO panel. New Microbiol 35:73\u201376.","journal-title":"New Microbiol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.021"},{"key":"e_1_3_2_26_2","volume-title":"Eravacycline package insert","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. 2019. Eravacycline package insert. U.S. FDA, Bethesda, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf."},{"key":"e_1_3_2_27_2","volume-title":"Omadacycline injection and oral products","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. 2019. Omadacycline injection and oral products. U.S. FDA, Bethesda, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm622612.htm."},{"key":"e_1_3_2_28_2","volume-title":"Eravacycline: injection products","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. 2019. Eravacycline: injection products. U.S. FDA, Bethesda, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm618563.htm."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_2_30_2","volume-title":"Omadacycline package insert","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. 2019. Omadacycline package insert. U.S. FDA, Bethesda, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01174-18"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_2_33_2","volume-title":"Tigecycline: injection products, FDA-identified interpretive criteria","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. 2019. Tigecycline: injection products, FDA-identified interpretive criteria. U.S. FDA, Bethesda, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm587585.htm."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00470-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00470-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:29:21Z","timestamp":1645478961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00470-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1128\/AAC.00470-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00470-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00470-19"}}